Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 314635
Compound means YH12852, which has the chemical structure set forth in this agreement, together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.
Licensor Patent Rights means all Patent Rights in the Territory that are Controlled by Licensor or any of its Affiliates as of the Effective Date or thereafter during the Term (other than Joint Patent Rights) that Cover any Compound or Product. The Licensor Patent Rights existing as of the Effective Date are set forth on Schedule 1.57; provided, however, that, if Licensor is acquired by a Third Party, â€œLicensor Patent Rightsâ€ shall exclude any Patent Rights that (a) are Controlled by such Third Party or the Affiliates of such Third Party (other than Licensor and Licensor Pre-Existing Affiliates) and (b) were not Controlled by Licensor or any of the Licensor Pre-Existing Affiliates immediately prior to the closing of such acquisition transaction; provided further that, if, after the closing of such acquisition, any such Licensor Excluded Affiliate has or acquires Control of any Patent Right that Covers the Development, Manufacture or Commercialization of any Compound or Product and that is used to Develop, Manufacture or Commercialize any such Compound or Product, such additional Patent Right that is Controlled by such Licensor Excluded Affiliate shall be included in Licensor Patent Rights.
9,890,138 – Diaminopyrimidine derivatives and processes for the preparation thereof
10,227,330 – Diaminopyrimidine derivatives and processes for the preparation thereof
9,850,227 – Diaminopyrimidine derivatives and processes for the preparation thereof
Licensee is a global pharmaceutical company offering one-stop custom synthesis services of active pharmaceutical products (APIs) and intermediates.
YH12852 is a novel, potent and highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. Other 5-HT receptor agonists with less 5-HT4 selectivity have been shown to successfully treat GI mobility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia and gastroparesis.
IPSCIO Record ID: 369326
TZP-101 means Licensorâ€™s proprietary ghrelin agonist known as TZP-101 (ulimorelin), having the chemical structure set forth in Agreement, including any salt, ester, solvate, polymorphic form, stereoisomer, metabolite, and pro-drug thereof.
Product means any pharmaceutical product comprising TZP-101 as an active ingredient irrespective of its formulation.
US 7,476,653 – Macrocyclic modulators of the ghrelin receptor
Licensor Product-Specific Patent means (a) the Patents set forth and (b) any other Patent that becomes Controlled by Licensor or its Affiliates at any time after the Effective Date (including Licensor Sole Patents but excluding Licensorâ€™s interest in any Joint Patents) that (i) is necessary for Licensee and/or its Affiliates to have rights under in order to Develop, manufacture, use and/or Commercialize TZP-101 and/or Products in the Field; and (ii) is not a Licensor Other-Product Patent.
US 7,452,862 – Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
Licensor Other-Product Patent means (a) the Patents set forth and (b) any other Patent that becomes Controlled by Licensor or its Affiliates after the Effective Date (including Licensor Sole Patents but excluding Licensorâ€™s interest in any Joint Patents) that (i) is necessary for Licensee and/or its Affiliates to have rights under in order to Develop, manufacture, use and/or Commercialize TZP-101 and/or Products in the Field; and (ii) covers any of Licensorâ€™s proprietary technology (A) that is generally applicable or can be applied to Licensorâ€™s discovery or development program in addition to the development program relating to TZP-101 and Product, or (B) that is applicable or can be applied to one or more compounds or products in addition to TZP-101 or Product, or (C) that covers the composition of matter of, or the method of discovering, making or using, any compounds or products (or any design, component, formulation or part thereof) in addition to TZP-101 or Product.
US 7,491,695 – Methods of using macrocyclic modulators of the ghrelin receptor
The deal is for development of a treatment targeting diseases of the muscles of the gastrointestinal track – called gastrointestinal dysmotility –
IPSCIO Record ID: 344539
For the Development and Commercialization License, Licensor grants an exclusive, even as to Licensor, right and license, under the Licensor Intellectual Property, to Develop Selected Compounds into Licensed Products intended for use in the Field in the Territory, and make and have made, use, offer for sale, sell, have sold and import Selected Compounds and Licensed Products in the Field in the Territory.
For the Grant of Certain Jointly Developed Methyl Gene Collaboration Intellectual Property for use Outside the Field, Licensor grants a perpetual, irrevocable, non-exclusive right and license to use, solely outside the Field, Licensor Collaboration Intellectual Property that is Formulation Technology or Know-How that directly relates to the physicochemical property pharmacokinetics/pharmacodynamics relationship in ocular tissue, and is jointly developed, conceived or created by or on behalf of Licensor and/or its Affiliates, on the one hand, and by or on behalf of Licensee and/or its Affiliates, on the other hand.
Inhibitors of VEOF Receptor and HOF Receptor;
Inhibitors of Protein Tyrosine Kinase Activity;
Kinase Inhibitors and Uses Thereof;
Processes and Intermediates for Preparing Fused;
Heterocyclic Kinase Inhibitors;
Inhibitors of Protein Tyrosine Kinase Activity;
Inhibitors of Kinase Activity.
A Compound is a molecule that is a small molecule that is a small molecule tyrosine kinase inhibitor as its main mechanism of action, and any salts, hydrates, solvates, polymorphs, free base, isomers, prodrugs, metabolites and/or liposomal or other formulations thereof or other compositions consisting of such molecule non-covalently bonded with other moieties, but excluding any derivative of such molecule in which the chemical structure of such molecule is altered.
IPSCIO Record ID: 355917
Compound means RX-3117 (fluorocyclopentenylcytosine or also known as roducitabine) [which is a cytidine analog, similar to gemcitabine,][with a sequence of 4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl] pyrimidin-2-one] together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures or compositions thereof covered by Licensor Intellectual Property, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its Affiliates or Sublicensees.
7,405,214 – Nucleoside derivatives and therapeutic use thereof
9,782,410 – Fluorocyclopentenylcytosine methods of use
IPSCIO Record ID: 336365
For Research and Manufacturing License Outside the Territory, Licensor grants a non-exclusive license, with the right to sublicense, under the Licensor Patents that cover outside of the Territory and the Licensor Know-How and Licensors rights under the Joint Inventions and Joint Patents, to research, develop and manufacture the Licensed Molecules and Products outside the Territory solely for the purpose of advancing the research, development and commercialization of the Licensed Molecules and Products in the Field in the Territory.
Licensed Molecules shall mean any and all compounds that arc claimed or covered by an Licensor Patent, including, but not limited to PCAP-872, PCAP-831, PCAP-924 and PCAP-130, and the salts, metabolites and pro-drugs of such compounds.
Product shall mean a pharmaceutical product containing at least one Licensed Molecule, including all dosage forms, formulations, line extensions and modes of administration thereof.
The patents include
– Amino substituted diary [a,d.] Cycloheptene analogs as muscarinic agonists and methods of treatment of Neuropsychiatric disorders,
– Use of N-Desmethylclozapine and related compounds as dopamine stabilizing agents, and,
– Prodrugs of muscarinic agonists and methods of treatment of Neuropsychiatric disorders.